Part 1 Component of: The CompassHER2 Trials (COMprehensive use of Pathologic response ASSessment to optimize therapy in HER2-positive breast cancer)
NCT# 04266249
Description: This study is being done to evaluate the effect of decreasing chemotherapy in patients with breast cancer without evidence of remaining cancer after receiving pre-surgery chemotherapy and HER2-targeted therapy without compromising long-term survival.
Learn more about the EA1181 trial or call Phoenixville Hospital Research Office at 610-983-1811.
